MLN Matters Articles
MLN Matters® Articles
These Articles explain national Medicare policies on coverage, billing, and payment rules for specific provider types. Sometimes we explain information in an MLN Connects® newsletter message instead of an MLN Matters® Article. If there’s an Article or a newsletter message, you’ll find it in the “Provider Education” column.
The COVID-19 public health emergency (PHE) ended on May 11, 2023. View Infectious diseases for a list of waivers and flexibilities that were in place during the PHE.
You can filter by subject or Article number. To search all years, leave the Transmittal Year as "Any."
Displaying 6821 - 6830 of 8677
| Transmittal # | Issue Date Sort ascending | Subject | Implementation Date | CR # | Provider Education | Provider Education Release Date | Provider Education Revision Date |
|---|---|---|---|---|---|---|---|
| R234PI | Revision to Instructions Relating to Compliance Standards for Independent Diagnostic Testing… |
5856 | MM5856 | ||||
| R1418CP | New HCPCS Modifiers when Billing for Patient Care in Clinical Research Studies |
5805 | MM5805 | ||||
| R1419CP | January 2008 Integrated Outpatient Code Editor (I/OCE) Specifications Version 9.0 |
5865 | MM5865 | ||||
| R1416CP | Clarification of Bone Mass Measurement (BMM) Billing Requirements |
5847 | MM5847 | ||||
| R1415CP | Additional Payable C Drug Codes for January 1, 2008 in ASCs |
5885 | MM5885 | ||||
| R1417CP | January 2008 Update of the Hospital Outpatient Prospective Payment System (OPPS |
5912 | MM5912 | ||||
| R80NCD | Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions |
5818 | MM5818 | ||||
| R1413CP | Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions |
5818 | MM5818 | ||||
| R1408CP | Modification to the Model Medicare Redetermination Notice (for partly or fully unfavorable… |
5836 | MM5836 | ||||
| R1409CP | Correction to Pub. 100-04, Chapter 17, Section 100.2.1 |
5857 |
Page Last Modified:
09/06/2023 04:51 PM